Rhabdomyolysis associated with the use of tirzepatide
Introduction: Tirzepatide is one of the commonly used combined glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonists for weight loss in recent years. There are significant advantages of these medications for weight reduction, improved glycaemic control and c...
Saved in:
| Main Authors: | Kunal Sonavane, Pallavi Shirsat, Gautam Agrawal, Bhawna Agarwal |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMC MEDIA SRL
2025-04-01
|
| Series: | European Journal of Case Reports in Internal Medicine |
| Subjects: | |
| Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/5392 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case Report: Rhabdomyolysis following initiation of tirzepatide
by: Jonas Michael Bodanowitz, et al.
Published: (2025-08-01) -
The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort
by: Eman A. Toraih, et al.
Published: (2025-04-01) -
Tirzepatide – a new hope for type 2 diabetes mellitus and obesity management. A literature review.
by: Izabela Stawicka, et al.
Published: (2024-11-01) -
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01) -
Efficacy and Safety of Tirzepatide in the Treatment of Obesity in Adults: A Comprehensive Review
by: Karolina Skonieczna, et al.
Published: (2025-05-01)